Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.
PER Pulse™ Recaps
for the 3rd Annual Miami Lung Cancer Conference® focus on clinical pearls from the expert Medical Crossfire® panel discussions regarding key therapeutic areas including immunotherapy, oncogene-targeted therapy, and patients with a poor performance status.
This activity is supported by an educational grant from Astellas, AstraZeneca, Bristol-Myers Squibb, Celgene, Clovis Oncology, Foundation Medicine, Inc., Genentech, Inc., Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
This edition of Medical Crossfire®, filmed in conjunction with the 3rd Annual Miami Lung Cancer Conference®, is designed to provide a dynamic discussion of current and evolving paradigms in the treatment of lung cancer, including immunotherapies in development, molecular subsets, targeted agents in development, and the role of cytotoxic agents in the molecular age.
Our Program Chairs, Thomas J. Lynch, Jr., MD, and Heather A. Wakelee, MD, and our expert faculty, Charu Aggarwal, MD, MPH, Christina Baik, MD, MPH, Sarah B. Goldberg, MD, MPH, Rebecca S. Heist, MD, MPH, Edward S. Kim, MD, Sukhmani K. Padda MD, Rathi Pillai, MD, Karen L. Reckamp, MD, Gregory Riely, MD, PhD, and Thomas Stinchcombe, MD, will emphasize the cutting-edge clinical research that will shape the therapy of lung cancer in the near future. Our community oncology representatives, Debra S. Brandt, MD, and Carrie B. Wasserman, MD, will complement the academic perspective provided by our faculty.
Each brief, 10-minute presentation will be followed by an extensive question-and-answer segment led by either, Dr. Lynch or Dr. Wakelee. This extended discussion format will allow ample time for examining the nuances and challenges faced by clinicians in everyday practice, and include a discussion of strategies for applying emerging data to clinical practice to improve outcomes for patients.
Instructions For This Activity & Receiving Credit
This educational activity is directed toward oncologists involved in the treatment and management of patients with lung cancers. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, fellows, and other health care professionals, interested in the treatment of lung cancers, may also participate.
Thomas J. Lynch, Jr., MD
Chairman and Chief Executive Officer
Massachusetts General Physicians Organization
Heather A. Wakelee, MD
Associate Professor, Medicine (Oncology)
Stanford University Medical Center
Charu Aggarwal, MD, MPH
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Christina Baik, MD, MPH
Thoracic, Head and Neck Medical Oncology Seattle Cancer Care Alliance Fred Hutchinson Cancer Research Center University of Washington
Debra S. Brandt, DO
Smilow Cancer Hospital at Yale-New Haven
New Haven, CT
Sarah B. Goldberg, MD, MPH
Assistant Professor of Internal Medicine
Yale Cancer Center
New Haven, CT
Rebecca S. Heist, MD, MPH
Assistant Professor, Department of Medicine, Harvard Medical School
Assistant Professor in Medicine
MGH Cancer Center, Massachusetts General Hospital
Edward S. Kim, MD
Chair of Solid Tumor Oncology and Investigational Therapeutics
Donald S. Kim Distinguished Chair for Cancer Research
Levine Cancer Institute
Carolinas HealthCare System
Sukhmani K. Padda MD
Instructor of Medicine
Stanford University Medical Center
Rathi Pillai, MD
Department of Hematology and Oncology
Winship Cancer Institute
Karen L. Reckamp, MD
City of Hope Comprehensive Cancer Center
Gregory Riely, MD, PhD
Vice Chair, Clinical Trials Office
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY
Tom Stinchcombe, MD
Thoracic Oncology Program
University of North Carolina at Chapel Hill
Chapel Hill, NC
Carrie B. Wasserman, MD
John Theurer Cancer Center
Hackensack UMC at Palisades
North Bergen, NJ
The following individuals have no relevant financial relationships with commercial interests to disclose:
Debra S. Brandt, MD; Rathi Pillai, MD; The staff of Physicians' Education Resource®, LLC.
The following individuals have relevant financial relationships with commercial interests to disclose:
Charu Aggarwal, MD, MPH -- Grant/Research Support: Nektar Therapeutics, Takeda; Consultant: Genentech; Christina Baik, MD, MPH -- Grant/Research Support: Celgene, Genentech, Novartis, Clovis, Millennium; Consultant: Clovis, Novartis; Sarah B. Goldberg, MD, MPH -- Grant/Research Support: AstraZeneca; Consultant: Clovis; Rebecca S. Heist, MD, MPH -- Consultant: Boehringer Ingelheim, Momenta Pharmaceuticals; Edward S. Kim, MD -- Consultant: Celgene, Eli Lilly, AstraZeneca; Thomas J. Lynch, Jr, MD -- Board of Directors for Bristol-Myers Squibb-Honoraria, Stock; Scientific Advisory Board for Arvinas-Honoraria, Stock; Stockholder in Infinity Pharmaceuticals, Stock; Patent Holder: Partners Healthcare EGFR mutation testing patent, Royalties; Sukhmani Padda, MD -- Consultant: Clovis; Karen L. Reckamp, MD -- Consultant: Amgen, Astellas, Ariad, Boehringer Ingelheim; Gregory Riely, MD, PhD -- Grant/Research Support: Roche, Novartis, Infinity, Millennium, GlaxoSmithKline, Pfizer; Consultant: Novartis; Thomas Stinchcombe, MD -- Grant/Research Support: Genentech, Merck Serono, BMS, Threshold Pharmaceuticals; Consultant: BMS, Ariad, Helsinn Therapeutics, Inc., BI, Celgene, AbbVie; Carrie B. Wasserman, MD -- Speaker's Bureau: INSYS Therapeutics. Heather A. Wakelee, MD -- Grant/Research Support: Novartis, BMS, Clovis, Xcovery, Celgene, Roche/Genentech, MedImmune, Pfizer, Lilly; Consultant: Peregrine Pharmaceuticals, Novartis, ACEA Biosciences.
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018